title: [Cervical spondylodiscitis: one pathogen may hide another].
abstract: A 54-year-old man presented with tuberculous spondylodiscitis associated to E. coli found in an intervertebral disc space needle biopsy. The enterobacteria came from a cholecystitis. The patient was cured by medical treatment, consisting in a non-surgical immobilization, antitubercular quadritherapy in association with a specific antibiotic treatment. No other case of spondylodiscitis caused by a mycobacterial coinfection pathogen has been reported so far.
authors.affiliation: Service des maladies infectieuses, département de médecine aiguë spécialisée, université de Versailles, Saint-Quentin-en-Yvelines, CHU Raymond-Poincaré, 104, boulevard Raymond-Poincaré, 92380 Garches, France.
authors.forename: J
authors.initials: J
authors.lastname: Toubiana
authors.forename: J
authors.initials: J
authors.lastname: Salomon
authors.forename: F
authors.initials: F
authors.lastname: Ader
authors.forename: C
authors.initials: C
authors.lastname: Perronne
authors.forename: R
authors.initials: R
authors.lastname: Carlier
authors.forename: L
authors.initials: L
authors.lastname: Bernard
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001372:Aza Compounds / Q000627:therapeutic use; D002574:Cervical Vertebrae / Q000000981:diagnostic imaging / Q000382:microbiology*; D002764:Cholecystitis / Q000150:complications / Q000188:drug therapy / Q000382:microbiology; D015299:Discitis / Q000188:drug therapy / Q000382:microbiology* / Q000628:therapy; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004926:Escherichia coli / Q000302:isolation & purification*; D004927:Escherichia coli Infections / Q000175:diagnosis / Q000188:drug therapy / Q000382:microbiology*; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D024841:Fluoroquinolones; D005602:France; D006801:Humans; D007103:Immobilization; D007538:Isoniazid / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009018:Morocco / Q000208:ethnology; D000077266:Moxifloxacin; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification*; D011718:Pyrazinamide / Q000008:administration & dosage / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D011859:Radiography; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D014399:Tuberculosis, Spinal / Q000188:drug therapy / Q000382:microbiology* / Q000628:therapy
chemical_list: D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D011718:Pyrazinamide; D004977:Ethambutol; D000077266:Moxifloxacin; D007538:Isoniazid; D012293:Rifampin